C. R. Bard
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, C. R. Bard sits in the top decile of US sponsors by registered trial count (#290 of 15,742 sponsors by registered trial count).
C. R. Bard: 75 sponsored US clinical trials, 4 recruiting.
C. R. Bard sponsors 75 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 56 completed. 10 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Arteriovenous Fistula, with 3 trials.
Top-decile sponsor footprint
C. R. Bard ranks in the top decile of sponsors by registered trial count (#290 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
56 of 69 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
75 total, page 2 of 2
Topical Antimicrobial Effectiveness Testing
NCT01314703
CONTINuous Infra-Inguinal Stenting Using the Bard® LifeStent® VascUlar Stent SysteMs ("CONTINUUM")
NCT00908947
Clinical Evaluation of Ajust™ in Stress Urinary Incontinence
NCT01290796
Assessment of the Precision of the Sherlock 3CG Tip Positioning System
NCT01275430
FLUENCY® PLUS Endovascular Stent Graft for In-stent Restenosis
NCT01257438
A Retrospective Study With Prospective Follow-Up of Complex Ventral Hernia Repair Utilizing the AlloMax Surgical Graft
NCT01205399
A Study of Complex Ventral Hernia Repair Utilizing the XenMatrix™ Surgical Graft With Component Separation
NCT01305486
A Retrospective Study With Prospective Follow-Up of Laparoscopic Ventral Hernia Repair Utilizing the Bard Sepramesh IP Composite
NCT01305473
Components of Chlorhexidine Gluconate Dressing
NCT01112020
Crosser Enters The Right Arterial Lumen
NCT01205386
Effectiveness of the Rapid Intravascular Start (RIVS) System Versus Conventional Catheter
NCT00914069
Study Of Hernia Repair Utilizing The Bard Ventrio Hernia Patch
NCT00866814
Post-Approval Study for the FLAIR Endovascular Stent Graft
NCT00677235
Study of HD Mesh Ablation System for Treatment of Paroxysmal Atrial Fibrillation
NCT00741611
Electrocardiogram (ECG) Guided Peripherally Inserted Central Catheter (PICC) Placement
NCT00742053
Transoral Gastric Volume Reduction as an Intervention for Weight Management
NCT00679848
FLAIR™ Delivery System Study
NCT00614315
Test for Pre Operative Skin Preparations
NCT00799812
Pilot Evaluation of the Application Procedure on the Antimicrobial Effects of 2 Antiseptics
NCT00692484
Preoperative Skin Preparation Evaluation
NCT00636480
Study of a Urethral Catheter Coated With Eluting Silver Salts (SUCCESS)
NCT00482547
Incisionless Treatment for Patients With Inadequate Weight Loss Following Roux-en-Y Gastric Bypass
NCT00394212
RF Ablation of Atrial Fibrillation
NCT00265629
Silver-Coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)
NCT00148642
Pivotal Study for the FLAIR Endovascular Stent Graft
NCT00678249
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
| Phase 3 | 7 |
| Phase 4 | 3 |
Therapeutic Areas
Where C. R. Bard enrollment is open (later-stage tilt)
4 recruiting of 75 indexed (5% open); 56 completed (75%).
Phase mix: 10 late (III/IV) vs 4 early (I/II) (later-stage heavy).
Top condition: Arteriovenous Fistula (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
C. R. Bard: open-pipeline peers nationwide
Peers matched on 75 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
C. R. Bard sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 75 trials (± recruiting share)
- ECOG-ACRIN Cancer Research Group · 75 trials · 16% recruiting
- Hartford Hospital · 75 trials · 11% recruiting
- Inova Health Care Services · 75 trials · 29% recruiting
- Ionis Pharmaceuticals · 76 trials · 12% recruiting
Sponsors near 5% open enrollment (± trial volume)
- Almirall, S.A. · 5% recruiting · 19 trials
- Cordis US · 5% recruiting · 19 trials
- Defense and Veterans Center for Integrative Pain Management · 5% recruiting · 19 trials
- DePuy Orthopaedics · 5% recruiting · 38 trials
Related
What to do with this C. R. Bard page
75 registered trials is a research-attention snapshot, not an endorsement of C. R. Bard or any single study.
- 4 of C. R. Bard's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Arteriovenous Fistula is the condition C. R. Bard studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Arteriovenous Fistula trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
C. R. Bard pipeline card: 75 registered trials from official public datasets.Report a data error.